Since, the BCR-ABL translocation is present in every case of CML and serves as a target for TKI therapy as well as a diagnostic marker for the illness, CML is a “poster child” of genetically based diagnosis and treatment. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.